Company

Rapport Therapeutics, Inc.

Rapport Therapeutics develops precision medicines for neurological disorders.

About

Founded in 2022, Rapport Therapeutics researches precision medicines for neurological disorders, using receptor-associated proteins to identify small molecule therapies for genetically and clinically confirmed targets. The company was established through a partnership between Third Rock Ventures and Janssen Neuroscience. In March 2023, it raised USD 100 million in Series A funding led by Third Rock Ventures, with participation from ARCH Venture Partners and Johnson and Johnson Innovation.

2Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in